Exelixis poised for breakout to all-time high after strong numbers and new stock buyback program!
Reading Time: 1 minute
Exelixis impressed on February 11 with strong numbers for the fourth quarter, exceeding expectations with revenues of $566.8 million and an EPS of $0.55. The biotech company has a strong growth driver in Cabometyx (Cabozantinib), which is approved for the treatment of certain types of kidney, liver, and thyroid cancers, with revenue in the last quarter increasing by 20% year-over-year. According to CEO Mike Morrissey, growth is expected to accelerate further in the coming quarters. Morrissey emphasized that the company aims to achieve annual revenues...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
